Sorriso Pharmaceuticals Announces Positive Phase 1b Results for SOR102 to Treat Ulcerative Colitis.

Dec 19, 2024•12 months ago

Salt Lake CityBiopharmaTherapeuticsPharmaceuticalBiotechnologyHealth Care

Product Description

Sorriso Pharmaceuticals reported positive Phase 1b clinical trial results for SOR102, an oral biologic targeting immune-mediated disease, showing favorable safety and efficacy in patients with ulcerative colitis. The company plans to advance SOR102 into Phase 2 development following these promising trial outcomes.

Company Information

Company

Sorriso Pharmaceuticals

Location

Salt Lake City, Utah, United States

About

Sorriso Pharmaceuticals is a biopharmaceutical company advancing a pipeline of disease-modifying antibodies for the treatment of immune-mediated diseases, including ulcerative colitis and Crohn’s disease. They are developing novel orally dosed antibodies that target critical pathways in conditions like inflammatory bowel disease. Their innovative approach aims to deliver effective therapies with minimal systemic exposure. Sorriso is committed to transforming patient care in autoimmune therapeutics.

Product Launch Insights

Based on market data

Market expansion signals

New product launches often coincide with market expansion initiatives

Sorriso Pharmaceuticals Announces Positive Phase 1b Results for SOR102 to Treat Ulcerative Colitis.

Product Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Product Launch Insights

Related People

Company Information